REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference
Feb 09, 2017 12:01 pm UTC| Business
ROCKVILLE, Md., Feb. 09, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based...
Feb 09, 2017 12:01 pm UTC| Business
AUSTIN, Texas, Feb. 09, 2017 -- Jones Energy, Inc. (NYSE:JONE) (“Jones Energy” or “the Company”) today provided its 2016 year-end reserves, an operations update and its initial 2017 capital budget and guidance. ...
Syndax Appoints Richard P. Shea as Chief Financial Officer
Feb 09, 2017 12:01 pm UTC| Business
WALTHAM, Mass., Feb. 09, 2017 -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer...
Syndax Appoints Richard P. Shea as Chief Financial Officer
Feb 09, 2017 12:01 pm UTC| Business
WALTHAM, Mass., Feb. 09, 2017 -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer...
Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 09, 2017 12:01 pm UTC| Business
NEW YORK, Feb. 09, 2017 -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment...
Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 09, 2017 12:01 pm UTC| Business
NEW YORK, Feb. 09, 2017 -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment...
Merus to Present at the Leerink Partners 6th Annual Global Healthcare Conference
Feb 09, 2017 12:01 pm UTC| Business
UTRECHT, The Netherlands, Feb. 09, 2017 -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...